A Phase I/II, Open Label, Dose-Escalating Study Evaluating the Safety and Efficacy of the Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody EMD 72000 (Matuzumab) in Combination with the EGFR Tyrosine Kinase Inhibitor Tarceva (Erlotinib) in Subjects with Recurrent Advanced Non-Small-Cell Lung Cancer.

Trial Profile

A Phase I/II, Open Label, Dose-Escalating Study Evaluating the Safety and Efficacy of the Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody EMD 72000 (Matuzumab) in Combination with the EGFR Tyrosine Kinase Inhibitor Tarceva (Erlotinib) in Subjects with Recurrent Advanced Non-Small-Cell Lung Cancer.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2011

At a glance

  • Drugs Erlotinib; Matuzumab
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Merck KGaA
  • Most Recent Events

    • 31 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top